Quality of life in patients with blepharospasm.

Abstract

OBJECTIVES:

Administration of botulinum neurotoxin A (BONT/A) is a common and effective treatment of blepharospasm. There is, however, no information regarding the emotional and social well-being of patients with blepharospasm and patient acceptance of BONT/A therapy. The purpose of this study was to investigate aspects of quality of life of patients with blepharospasm and level of patient satisfaction with treatment.

MATERIAL AND METHODS:

Fifty-one patients with blepharospasm who had been treated with BONT/A for years completed a questionnaire providing information about quality of life.

RESULTS:

Results revealed reductions in social and emotional well-being of patients but, nonetheless, good acceptance of BONT/A therapy. The positive effects of BONT/A therapy were, however, accompanied by fear of a decreasing effect of BONT/A injections.

CONCLUSION:

Although the objective findings following BONT/A injections in the treatment of blepharospasm are appreciated by the patients, their well-being is affected by fears and depression.

• Authors: O Tucha, M Naumann, D Berg, G L Alders, K W Lange
• Journal: Acta neurologica Scandinavica (Acta Neurol Scand) Vol. 103 Issue 1 Pg. 49-52 (Jan 2001) ISSN: 0001-6314 [Print] Denmark
• PMID: 11153888 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Botulinum Toxins, Type A

Topics

• Aged
• Blepharospasm (drug therapy, psychology)
• Botulinum Toxins, Type A (administration & dosage)
• Female
• Humans
• Injections, Intramuscular
• Male
• Middle Aged
• Patient Acceptance of Health Care (psychology)
• Patient Satisfaction
• Quality of Life
• Sick Role
• Social Adjustment